GlassScriptPhysician profile
Landry Shipman
NPI 1851975874
$2,746.79
in general payments reported to CMS, 2019-2025
25 companies · $1,972 in 2025
The $1,972 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $774 · 2025: $1,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $614.95 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $359.00 | 2024-2025 | |
| Pfizer INC. | $279.52 | 2025 | |
| Novo Nordisk INC | $272.41 | 2024-2025 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $235.93 | 2024-2025 | |
| Lilly USA, LLC | $156.65 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $143.34 | 2024 | Evenity, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $127.30 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.30 | 2025 | Jardiance |
| Abbott Laboratories | $51.66 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $50.04 | 2025 | Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $47.09 | 2025 | Zenpep, Vowst |
| Sanofi Pasteur INC. | $46.62 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.31 | 2025 | |
| Sumitomo Pharma America, INC. | $36.13 | 2024-2025 | Gemtesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.33 | 2024 | Spravato |
| Exact Sciences Corporation | $33.72 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $28.41 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Corcept Therapeutics | $20.42 | 2024 | Korlym |
| Lundbeck LLC | $20.28 | 2024 | Rexulti |
| Cranial Technologies, INC | $20.12 | 2024 | Doc Band |
| Biomarin Pharmaceutical INC. | $17.85 | 2025 | Voxzogo 1.2mg |
| Novartis Pharmaceuticals Corporation | $16.69 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.54 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $5.18 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Landry Shipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.